Product Description
Zaleplon is a pyrazolopyrimidine hypnotic agent which is indicated for the short term (2 to 4 weeks) management of insomnia. Zaleplon 5 and 10 mg at bedtime (usual recommended doses) significantly reduced sleep latency compared with placebo in clinical trials in nonelderly and elderly patients with insomnia. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/10983740/)
Mechanisms of Action: GABA Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Inhalant,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Egypt | European Medicines Agency | Germany | Hungary | India | Ireland | Israel | Italy | Jordan | Korea | Lithuania | New Zealand | Peru | Poland | Portugal | Romania | Russia | Sweden | Taiwan | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|